Telix Pharmaceuticals Limited

Telix and Grand Pharmaceutical Group Limited (Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP study of TLX250-CDx PET imaging of clear cell renal cell carcinoma. The patient was successfully dosed and imaged at Beijing Cancer Hospital in Beijing, China. The multi-centre, Phase III registration study is designed to bridge to Telix’s successful global Phase III ZIRCON study, which met all co-primary and secondary endpoints. The clinical data from ZIRCON-CP is intended to support future marketing authorisation applications for this breakthrough technology in the Greater China region. Read more on our website here: https://bit.ly/3CO8FBQ TLX250-CDx has not received a marketing authorisation in any jurisdiction.

A pan-cancer target like fibroblast activation protein or FAP may seem like science fiction, but it is widely considered to be one of the most promising targets for both cancer imaging and therapy. Follow the link to read our interactive FAP explainer and learn more about the potential of this target and Telix’s theranostic approach: https://bit.ly/48UGrkE

Fibroblast activation protein or FAP has emerged in recent years as one of the most promising pan-cancer targets for both imaging and therapy. Here Univ.-Prof. Dr. Frederik Giesel, MD, MBA, a key opinion leader in FAP-targeted radiopharmaceuticals, speaks about the potential of the target and why it is such a ‘groundbreaking’ development in oncology. Through the recent acquisition and in-licensing of a suite of FAP-targeted compounds, Telix is positioning itself to deliver on the promise of FAP-targeted theranostics. To learn more about this target and Telix’s approach, visit our website here: https://bit.ly/48UGrkE

Telix today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and prostate cancers. The therapeutic and diagnostic candidates were developed by Prof. Dr. Frank Rösch and collaborators at the Institute of Nuclear Chemistry at the Johannes Gutenberg University Mainz and have clinically demonstrated safety profile and efficacy. Read more on our website here: https://bit.ly/4fwnabH

The short shelf life of radiopharmaceuticals makes it essential to have efficient and reliable manufacturing and supply chains. Telix Manufacturing Solutions (TMS) is a global network of facilities, infrastructure and technologies with the capability to supply patient doses worldwide and deliver on the promise of nuclear medicine. Our investment in vertically integrated supply chain and manufacturing is helping Telix to meet the unique demands of a rapidly growing market. This will support development and ultimately commercialisation for the benefit of Telix, our partners and patients. Watch the video below to learn more about the TMS global footprint.

Telix MD and Group CEO, Dr Chris Behrenbruch, will present next week at the Jefferies London Healthcare Conference 2024. We're looking forward to showcasing Telix’s theranostic pipeline, medical technologies, and manufacturing and supply chain capabilities at the largest healthcare-dedicated conference in Europe. 📅 Wednesday, 20 November 2024 🕘 8:30am GMT (7:30pm AEDT) 🔗Register here: https://lnkd.in/gyZUWAVD

Today marked an important milestone for Telix as we commenced trading on the Nasdaq under the ticker “TLX”. We reaffirm our founding commitment to building a world-class global business, that delivers on the promise of precision medicine through targeted radiation, helping people with cancer and rare diseases live longer, better quality lives. Listing on Nasdaq is key towards achieving these goals, and an appropriate step given our growth trajectory, leadership position in radiopharmaceuticals and expanding footprint in North America. We would like to thank the many who have helped us reach this point. Read more on our website here: https://lnkd.in/ezQW5kPB This does not constitute an offer to sell or the solicitation of an offer to buy any securities of Telix.

Telix today announces that is has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce the alpha-emitting isotope, actinium-225. This provides Telix with both an additional commercial source of the isotope and access to a platform technology that enables highly efficient, scalable production for use in the development of next generation targeted alpha therapies, a strategic focus for Telix. Read more on our website here: https://lnkd.in/gBRdd7pf

On Veterans Day, we honor all Veterans for their selfless service. Veterans are twice as likely to be diagnosed with prostate cancer than the general population – a fact that patient advocate, Mike Crosby, wants more Veterans to be aware of and to act on by getting tested. Today, we also acknowledge the incredible Veterans working at Telix. Their dedication to our mission is a testament to the strength and commitment shown by Veterans everywhere. Thank you to all who have served, and to those who continue to serve🎗️ #VeteransDay #HonoringService

Thank you for joining Telix at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg, Germany. As the largest gathering of nuclear medicine professionals worldwide, we were pleased to have our extensive theranostic pipeline showcased in a range of oral presentations covering the Company’s late-stage programs. Our sponsored symposium brought together globally renowned key opinion leaders to discuss the pros and cons of small molecule- and antibody-based approaches in radiopharmaceuticals. And it was an honour to once again support the Sanjiv Sam Gambhir Young Investigator Award. We look forward to seeing you next year in Barcelona!